Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis.
about
Risk Factors for Acquired Rifamycin and Isoniazid Resistance: A Systematic Review and Meta-AnalysisInactivation of the Mycobacterium tuberculosis Antigen 85 Complex by Covalent, Allosteric InhibitorsPharmacokinetics of rifabutin in Japanese HIV-infected patients with or without antiretroviral therapyRandomised pharmacokinetic trial of rifabutin with lopinavir/ritonavir-antiretroviral therapy in patients with HIV-associated tuberculosis in VietnamNine- to Twelve-Month Anti-Tuberculosis Treatment Is Associated with a Lower Recurrence Rate than 6-9-Month Treatment in Human Immunodeficiency Virus-Infected Patients: A Retrospective Population-Based Cohort Study in TaiwanPipeline of drugs for related diseases: tuberculosisHIV and Tuberculosis: a Deadly Human SyndemicInsights into the pharmacokinetic properties of antitubercular drugs.Understanding pharmacokinetics to improve tuberculosis treatment outcome.Plasma drug activity assay for treatment optimization in tuberculosis patients.Population pharmacokinetic drug-drug interaction pooled analysis of existing data for rifabutin and HIV PIsMortality among patients with tuberculosis requiring intensive care: a retrospective cohort study.Recognition and management of significant drug interactions in HIV patients: challenges in using available data to guide therapyImportance of Drug Pharmacokinetics at the Site of ActionTreatment Options for HIV-Associated Tuberculosis.Genetic Determinants of the Pharmacokinetic Variability of Rifampin in Malawian Adults with Pulmonary Tuberculosis.Effects of four different meal types on the population pharmacokinetics of single-dose rifapentine in healthy male volunteers.Effects of tuberculosis, race, and human gene SLCO1B1 polymorphisms on rifampin concentrations.Management of HIV-associated tuberculosis in resource-limited settings: a state-of-the-art review.Pharmacokinetic interaction study of ritonavir-boosted saquinavir in combination with rifabutin in healthy subjectsExposure to rifampicin is strongly reduced in patients with tuberculosis and type 2 diabetes.Effects of dosage, comorbidities, and food on isoniazid pharmacokinetics in Peruvian tuberculosis patientsIsoniazid, rifampin, and pyrazinamide plasma concentrations in relation to treatment response in Indonesian pulmonary tuberculosis patients.Randomized pharmacokinetic evaluation of different rifabutin doses in African HIV- infected tuberculosis patients on lopinavir/ritonavir-based antiretroviral therapyImpact of nonlinear interactions of pharmacokinetics and MICs on sputum bacillary kill rates as a marker of sterilizing effect in tuberculosis.Rifampin monoresistant tuberculosis and HIV comorbidity in California, 1993-2008: a retrospective cohort studyTreatment of tuberculosis with rifamycin-containing regimens in immune-deficient miceThe SLCO1B1 rs4149032 polymorphism is highly prevalent in South Africans and is associated with reduced rifampin concentrations: dosing implications.Pharmacokinetics of isoniazid, rifampicin, pyrazinamide and ethambutol in Indian children.Therapeutic drug monitoring in the treatment of active tuberculosisExposure to total and protein-unbound rifampin is not affected by malnutrition in Indonesian tuberculosis patients.The ethics of a clinical trial when the protocol clashes with international guidelines.Limited sampling strategy and target attainment analysis for levofloxacin in patients with tuberculosis.Low Serum Concentrations of Moxifloxacin, Prothionamide, and Cycloserine on Sputum Conversion in Multi-Drug Resistant TB.Experience with rifabutin replacing rifampin in the treatment of tuberculosis.Rifampin resistance and diabetes mellitus in a cross-sectional study of adult patients in rural South India.Early bactericidal activity of high-dose rifampin in patients with pulmonary tuberculosis evidenced by positive sputum smears.Pharmacokinetics of rifampin in Peruvian tuberculosis patients with and without comorbid diabetes or HIVTuberculosis drug development: ensuring people living with HIV are not left behind.TB and HIV Therapeutics: Pharmacology Research Priorities.
P2860
Q26781111-19F33F9A-459A-453C-8578-21D3DF807FAEQ27684704-F1E5397A-3B77-4BA1-A8AF-ABC007BA6FFBQ28535120-5F5CA2E6-B9BE-40D7-8EAF-1F9174FF1ED2Q28538952-C1045756-1244-48AF-A075-68C99271924FQ28551297-7DB36583-0A50-4A92-B441-ACD1F584A33CQ28818217-AD667787-DFB0-4E9E-BF73-75A4A5E87352Q30052157-F46C2D3A-F29E-4A67-B8E2-905CD5DC4086Q30251497-6D1BB5A2-E6BF-4D9C-A9CA-B067C4EF5B0BQ30411703-102C0282-5F83-4CD9-AD18-890BD15A83A4Q30426583-9C031F4E-3F1C-4CB7-9356-A0788C325AA3Q31041943-79A81CF9-53E0-490F-93C3-33425A3A8923Q33537492-064CBD26-5DB1-44B4-8E85-1019CB9D4127Q33644204-434E3C8B-8EBE-46BE-AAC2-1CE23DFDEEB8Q33648045-3ABC9392-458C-4DFE-9740-0E8242B6E6A4Q33813097-25F3BCAC-5524-466C-856D-D77907F1A773Q33843657-D2A93017-9F35-49C9-A2ED-C13D947BD367Q34045240-A91A8F63-847D-405D-A337-00DE8A014A96Q34150929-55087412-C2EB-44C1-9C02-09824437A31CQ34455442-E3E9A30B-0DB5-415A-BAE2-7D48B587DD91Q34528955-B991A17A-DC9C-42F9-96A4-06E0E168E21EQ34561741-3B78EE15-BD93-4ABF-BAA8-C5D3281D9124Q34597564-E3093F8E-EE21-4D52-9C5E-60758392BCC8Q34729493-8E5528B9-B094-4314-9494-1FA8AD0EB20DQ34778531-84AD0565-58DF-40F3-B514-A8FE1860A92FQ34922554-E0352383-DD90-4337-B950-4AE8AE0EA249Q34974157-2DF5EF74-B5D7-45B5-B301-6E5AD7A1A88EQ35042502-166059A4-D462-47B1-866F-39879F7189A0Q35191432-80186E16-82C9-4763-8450-F84F4BF515B1Q35215680-95ED6018-E8A2-42BE-BC26-E434DFC741BDQ35487794-65F6C549-D01B-43CA-A80D-6D0927B72068Q35584822-A3365192-628A-419E-A35E-6AC968F6A73CQ35719130-114AD957-1E81-4A49-A49C-3D72EA40F407Q35746184-84D86E0D-624A-4E6E-A1E7-31EE0DFD2445Q35778303-2ED0F8D6-0909-4822-8BD7-920BF520EE34Q35789741-5EF1682E-3065-4C1C-AA1C-DCE211948517Q35819438-31B551A6-DFF8-42FC-ABD5-B2ACA23965F3Q35912691-2F32549C-C947-4EFD-B02E-9DEAE27DE923Q35941434-A24F5B4E-CA31-4F07-B193-D9B504B425E2Q35991204-B389A816-B34E-4E3C-B0CD-F961CC680392Q36099838-10325D65-2E83-40EC-B8D5-4AD64BDF67C6
P2860
Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
Association between acquired r ...... nts with HIV and tuberculosis.
@en
Association between acquired r ...... nts with HIV and tuberculosis.
@nl
type
label
Association between acquired r ...... nts with HIV and tuberculosis.
@en
Association between acquired r ...... nts with HIV and tuberculosis.
@nl
prefLabel
Association between acquired r ...... nts with HIV and tuberculosis.
@en
Association between acquired r ...... nts with HIV and tuberculosis.
@nl
P2093
P2860
P356
P1476
Association between acquired r ...... nts with HIV and tuberculosis.
@en
P2093
Andrew Vernon
Brenda Jones
Charles A Peloquin
Claudia Silva-Trigo
Debra Benator
Marc Weiner
Thomas Hodge
Tuberculosis Trials Consortium
William Burman
P2860
P304
P356
10.1086/429321
P407
P577
2005-04-14T00:00:00Z